GlassScriptPhysician profile
Stephanie Lang
NPI 1043782931
$5,325.89
in general payments reported to CMS, 2019-2025
20 companies · $1,236 in 2025
The $1,236 reported for 2025 was more than what 84% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $477 · 2022: $782 · 2023: $1,438 · 2024: $1,393 · 2025: $1,236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,040 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,039.92 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,168.99 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $1,044.52 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Lundbeck LLC | $589.11 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $517.56 | 2022-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $341.73 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $318.91 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $286.21 | 2023-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $269.56 | 2021-2022 | |
| Alkermes, INC. | $184.07 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $173.93 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $136.76 | 2023-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $131.15 | 2023-2025 | Invega Sustenna, Invega Trinza |
| Indivior INC. | $47.85 | 2023-2024 | Sublocade |
| Corium, LLC | $24.55 | 2023 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $17.23 | 2024 | Trintellix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braeburn INC. | $16.11 | 2024 | Brixadi |
| Supernus Pharmaceuticals, INC. | $14.65 | 2025 | Qelbree |
| Tris Pharma INC | $14.61 | 2024 | Dyanavel Xr |
| Collegium Pharmaceutical, INC. | $14.50 | 2025 | Jornay Pm |
| Allergan, INC. | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.